Alpha Fusion, Curadh MTR Partner on Astatine-211 Drugs

Alpha Fusion, Inc. and Curadh MTR, Inc. They plan to create a strategic partnership. This includes a Joint Venture to enhance global radiopharmaceutical development with Astatine-211 (At-211).

This partnership brings together Alpha Fusion’s expertise in At-211 drug discovery and early clinical research in Japan. It also combines Curadh’s global skill in radiopharmaceutical development.

The Joint Venture will develop lead At-211 products in the U.S. It will also build a strong pipeline of next-gen radiopharmaceuticals.

Also Read: Axcelead, A2 Healthcare Unite for Pharma R\&D in Japan

The announcement took place at the World Astatine Community Meeting. The leaders from both companies talked about At-211’s treatment potential and their partnership’s future.